foscarnet has been researched along with AIDS Seroconversion in 18 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ganciclovir and Foscarnet were compared in an open randomised trial as treatment and secondary prophylaxis of cytomegalovirus (CMV) retinitis in patients with AIDS." | 9.07 | Foscarnet and Ganciclovir in the treatment of CMV retinitis in AIDS patients: a randomised comparison. ( Gazzard, BG; Harman, C; Mathalone, B; Mitchell, S; Moyle, G, 1992) |
| "Ganciclovir and Foscarnet were compared in an open randomised trial as treatment and secondary prophylaxis of cytomegalovirus (CMV) retinitis in patients with AIDS." | 5.07 | Foscarnet and Ganciclovir in the treatment of CMV retinitis in AIDS patients: a randomised comparison. ( Gazzard, BG; Harman, C; Mathalone, B; Mitchell, S; Moyle, G, 1992) |
| "Sequential visual field testing is an extremely helpful adjunct to ophthalmoscopy and fundus photography in the management of cytomegalovirus (CMV) retinitis with the antiviral agents ganciclovir or foscarnet in patients with the acquired immune deficiency syndrome (AIDS)." | 3.68 | Visual field testing in the management of cytomegalovirus retinitis. ( Bachman, DM; Bruni, LM; DiGioia, RA; Harris, PJ; McMackin, CM; Pistole, MC; Thomas, RM; Ward, DJ, 1992) |
| "Most foscarnet plasma levels were below the assay limit of detection (33 microM) with only 4/30 levels detectable after D5W and 8/30 after ranitidine." | 2.69 | The effect of increasing gastric pH upon the bioavailability of orally-administered foscarnet. ( Barditch-Crovo, PA; Gambertoglio, J; Hafner, R; Kornhauser, DM; Kuwahara, S; Lietman, PS; Nerhood, LJ; Petty, BG, 1998) |
| " However, patients with positive baseline CMV blood cultures had a significantly more shallow dose-response curve." | 2.68 | Relationship between foscarnet exposure, baseline cytomegalovirus (CMV) blood culture and the time to progression of CMV retinitis in HIV-positive patients. ( Aweeka, F; Drusano, GL; Eaton, C; Gambertoglio, J; Jacobson, M; Lane, HC; Martin-Munley, S; Polis, M, 1996) |
| " Terminal elimination half-life remained unchanged at 5." | 1.30 | Renal excretion and pharmacokinetics of foscarnet in HIV sero-positive patients: effect of probenecid pretreatment. ( Gazzard, BG; Higgs, CJ; Lant, AF; Noormohamed, FH; Youle, MS, 1997) |
| " The mean peak concentration in plasma following the intravenous administration of foscarnet (90 mg/kg) was 887." | 1.30 | Pharmacokinetics and absolute bioavailability of oral foscarnet in human immunodeficiency virus-seropositive patients. ( Gazzard, BG; Higgs, CJ; Lant, AF; Martin-Munley, S; Noormohamed, FH; Youle, MS, 1998) |
| "Effective diagnosis and treatment of cytomegalovirus infection of the nervous system in AIDS patients has been limited by a lack of sensitive diagnostic measures." | 1.29 | Prognosis and response to therapy of cytomegalovirus encephalitis and meningomyelitis in AIDS. ( Cohen, BA, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 18 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Costagliola, D | 1 |
| Mary-Krause, M | 1 |
| Cello, JP | 1 |
| Nelson, MR | 1 |
| Hawkins, DA | 1 |
| Gazzard, BG | 5 |
| Antinori, S | 1 |
| Esposito, R | 1 |
| d'Arminio Monforte, A | 1 |
| Moroni, M | 1 |
| Navarro, JF | 1 |
| Quereda, C | 2 |
| Moreno, A | 1 |
| Cohen, BA | 1 |
| Drusano, GL | 1 |
| Aweeka, F | 1 |
| Gambertoglio, J | 2 |
| Jacobson, M | 1 |
| Polis, M | 1 |
| Lane, HC | 1 |
| Eaton, C | 1 |
| Martin-Munley, S | 3 |
| Noormohamed, FH | 3 |
| Youle, MS | 3 |
| Higgs, CJ | 2 |
| Lant, AF | 3 |
| Barditch-Crovo, PA | 1 |
| Petty, BG | 1 |
| Nerhood, LJ | 1 |
| Kuwahara, S | 1 |
| Hafner, R | 1 |
| Lietman, PS | 1 |
| Kornhauser, DM | 1 |
| Tang, B | 1 |
| Moyle, G | 1 |
| Harman, C | 1 |
| Mitchell, S | 1 |
| Mathalone, B | 1 |
| Bachman, DM | 1 |
| Bruni, LM | 1 |
| DiGioia, RA | 1 |
| Harris, PJ | 1 |
| McMackin, CM | 1 |
| Pistole, MC | 1 |
| Thomas, RM | 1 |
| Ward, DJ | 1 |
| Malin, A | 1 |
| Miller, RF | 1 |
| Coker, RJ | 1 |
| Tomlinson, D | 1 |
| Horner, P | 1 |
| Migdal, C | 1 |
| Harris, JR | 1 |
| Green, ST | 1 |
| Nathwani, D | 1 |
| Goldberg, DJ | 1 |
| Mack, DJ | 1 |
| Kennedy, DH | 1 |
| Charmot, G | 1 |
| Ingrand, D | 1 |
| Simon, F | 1 |
| Kernbaum, S | 1 |
| Fegueux, S | 1 |
| De Truchis, P | 1 |
| Coulaud, JP | 1 |
| Youle, M | 1 |
| Chanas, A | 1 |
| Gazzard, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Increasing Gastric pH Upon the Bioavailability of Orally Administered Phosphonoformic Acid (Foscarnet)[NCT00000964] | Phase 1 | 6 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for foscarnet and AIDS Seroconversion
| Article | Year |
|---|---|
Foscarnet in the treatment of cytomegalovirus esophagitis.
Topics: Cytomegalovirus Infections; Esophagitis; Foscarnet; HIV Seropositivity; HIV-1; Humans | 1993 |
Relationship between foscarnet exposure, baseline cytomegalovirus (CMV) blood culture and the time to progression of CMV retinitis in HIV-positive patients.
Topics: Analysis of Variance; Antiviral Agents; Cytomegalovirus Infections; Cytomegalovirus Retinitis; Disea | 1996 |
The effect of increasing gastric pH upon the bioavailability of orally-administered foscarnet.
Topics: Administration, Oral; Antiviral Agents; Biological Availability; Chromatography, High Pressure Liqui | 1998 |
Foscarnet and Ganciclovir in the treatment of CMV retinitis in AIDS patients: a randomised comparison.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Treatment of acquired immune deficiency syndrome (AIDS)-related pneumonitis with foscarnet: a double-blind placebo controlled study.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; D | 1990 |
13 other studies available for foscarnet and AIDS Seroconversion
| Article | Year |
|---|---|
Can antiviral agents decrease the occurrence of Kaposi's sarcoma? Clinical Epidemiology Group from Centres d'Information et de Soins de l'Immunodéficience Humaine.
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Antiviral Agents; Bias; Female; Follow-Up Studies; | 1995 |
Evaluation of AIDS-related diarrhea.
Topics: Adult; Ampulla of Vater; Biopsy; Cholangiopancreatography, Endoscopic Retrograde; Cholangitis, Scler | 1993 |
Foscarnet treatment of chronic hepatitis B in an HIV-positive patient.
Topics: Adult; Chronic Disease; Foscarnet; Hepatitis B; HIV Seropositivity; Humans; Male | 1993 |
Renal tubular acidosis following treatment with foscarnet.
Topics: Acidosis, Renal Tubular; Adult; Antiviral Agents; Cytomegalovirus Retinitis; Foscarnet; HIV Seroposi | 1995 |
Prognosis and response to therapy of cytomegalovirus encephalitis and meningomyelitis in AIDS.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Base Sequence; Cerebrospi | 1996 |
Renal excretion and pharmacokinetics of foscarnet in HIV sero-positive patients: effect of probenecid pretreatment.
Topics: Adult; Antiviral Agents; Foscarnet; HIV Seropositivity; Humans; Kidney; Male; Middle Aged; Probeneci | 1997 |
Pharmacokinetics and absolute bioavailability of oral foscarnet in human immunodeficiency virus-seropositive patients.
Topics: Administration, Oral; Adult; Antiviral Agents; Biological Availability; Foscarnet; HIV; HIV Infectio | 1998 |
Foscarnet-induced changes in plasma concentrations of total and ionized calcium and magnesium in HIV-positive patients.
Topics: Adult; Antiviral Agents; Calcium; Foscarnet; HIV Seropositivity; Humans; Magnesium; Male; Middle Age | 1996 |
Visual field testing in the management of cytomegalovirus retinitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Eye Infe | 1992 |
Foscarnet-induced hypokalaemia.
Topics: Cytomegalovirus Infections; Female; Foscarnet; HIV Seropositivity; HIV-1; Humans; Hypokalemia; Male; | 1992 |
Treatment of cytomegalovirus retinitis with ganciclovir and foscarnet.
Topics: Adult; Cytomegalovirus Infections; Drug Combinations; Foscarnet; Ganciclovir; HIV Seropositivity; Hu | 1991 |
Generalised cutaneous rash associated with foscarnet usage in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Drug Eruptions; Foscarnet; Ganciclovir; | 1990 |
[Aciclovir-resistant herpes simplex virus infection in an immuno-depressed patient. Favourable effect of foscarnet].
Topics: Acyclovir; Antiviral Agents; Drug Resistance, Microbial; Foscarnet; Herpes Simplex; HIV Seropositivi | 1990 |